Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP526337.RAgXr0GtUOi-veeqwu3L-UZ0Lbp8nB0I2jeXpzjFsliMs130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP526337.RAgXr0GtUOi-veeqwu3L-UZ0Lbp8nB0I2jeXpzjFsliMs130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP526337.RAgXr0GtUOi-veeqwu3L-UZ0Lbp8nB0I2jeXpzjFsliMs130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP526337.RAgXr0GtUOi-veeqwu3L-UZ0Lbp8nB0I2jeXpzjFsliMs130_provenance.
- NP526337.RAgXr0GtUOi-veeqwu3L-UZ0Lbp8nB0I2jeXpzjFsliMs130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526337.RAgXr0GtUOi-veeqwu3L-UZ0Lbp8nB0I2jeXpzjFsliMs130_provenance.
- NP526337.RAgXr0GtUOi-veeqwu3L-UZ0Lbp8nB0I2jeXpzjFsliMs130_assertion evidence source_evidence_literature NP526337.RAgXr0GtUOi-veeqwu3L-UZ0Lbp8nB0I2jeXpzjFsliMs130_provenance.
- NP526337.RAgXr0GtUOi-veeqwu3L-UZ0Lbp8nB0I2jeXpzjFsliMs130_assertion SIO_000772 16341239 NP526337.RAgXr0GtUOi-veeqwu3L-UZ0Lbp8nB0I2jeXpzjFsliMs130_provenance.
- NP526337.RAgXr0GtUOi-veeqwu3L-UZ0Lbp8nB0I2jeXpzjFsliMs130_assertion wasDerivedFrom befree-2016 NP526337.RAgXr0GtUOi-veeqwu3L-UZ0Lbp8nB0I2jeXpzjFsliMs130_provenance.
- NP526337.RAgXr0GtUOi-veeqwu3L-UZ0Lbp8nB0I2jeXpzjFsliMs130_assertion wasGeneratedBy ECO_0000203 NP526337.RAgXr0GtUOi-veeqwu3L-UZ0Lbp8nB0I2jeXpzjFsliMs130_provenance.
- befree-2016 importedOn "2016-02-19" NP526337.RAgXr0GtUOi-veeqwu3L-UZ0Lbp8nB0I2jeXpzjFsliMs130_provenance.